G Goodall

484 total citations
19 papers, 367 citations indexed

About

G Goodall is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, G Goodall has authored 19 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Cardiology and Cardiovascular Medicine and 5 papers in Economics and Econometrics. Recurrent topics in G Goodall's work include Diabetes Treatment and Management (11 papers), Diabetes Management and Research (11 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). G Goodall is often cited by papers focused on Diabetes Treatment and Management (11 papers), Diabetes Management and Research (11 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). G Goodall collaborates with scholars based in United States, Switzerland and United Kingdom. G Goodall's co-authors include William J. Valentine, Michael Strupp, Heike Benecke, Eric Sarpong, Jayne Smith‐Palmer, Katrina Erny-Albrecht, Michael Brändle, Andrew Palmer, Michael Happich and Thomas Mittendorf and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetic Medicine and European Journal of Heart Failure.

In The Last Decade

G Goodall

17 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G Goodall United States 12 176 82 63 60 45 19 367
Giovanni Viscogliosi Italy 11 76 0.4× 17 0.2× 73 1.2× 79 1.3× 12 0.3× 19 370
J.‐P. Le Floch France 11 95 0.5× 10 0.1× 18 0.3× 45 0.8× 5 0.1× 24 286
D.V. Coppini United Kingdom 10 175 1.0× 28 0.3× 40 0.6× 28 0.5× 7 0.2× 16 410
Takeshi Momotsu Japan 9 40 0.2× 15 0.2× 28 0.4× 22 0.4× 9 0.2× 29 272
Jeff Mahon Canada 8 76 0.4× 35 0.4× 10 0.2× 58 1.0× 16 0.4× 12 275
Ida Juul Rasmussen Denmark 8 40 0.2× 35 0.4× 18 0.3× 24 0.4× 5 0.1× 17 241
Luc Sauriol Canada 10 189 1.1× 7 0.1× 19 0.3× 54 0.9× 64 1.4× 24 355
Gerardo Corigliano Italy 9 204 1.2× 8 0.1× 36 0.6× 51 0.8× 19 0.4× 18 427
Shuangling Xiu China 11 26 0.1× 25 0.3× 27 0.4× 24 0.4× 17 0.4× 20 275

Countries citing papers authored by G Goodall

Since Specialization
Citations

This map shows the geographic impact of G Goodall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Goodall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Goodall more than expected).

Fields of papers citing papers by G Goodall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Goodall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Goodall. The network helps show where G Goodall may publish in the future.

Co-authorship network of co-authors of G Goodall

This figure shows the co-authorship network connecting the top 25 collaborators of G Goodall. A scholar is included among the top collaborators of G Goodall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Goodall. G Goodall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Tarride, Jean‐Éric, et al.. (2019). <p>A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients</p>. ClinicoEconomics and Outcomes Research. Volume 11. 477–486. 21 indexed citations
2.
Goodall, G, et al.. (2018). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. Journal of Medical Economics. 22(4). 289–296. 24 indexed citations
3.
Verbrugghe, Peter, Herbert De Praetere, Bart Meuris, et al.. (2016). Cost analysis of minimally invasive compared to conventional mitral valve surgery. Acta cardiologica. Supplementum. 71(5). 527–535. 3 indexed citations
4.
Benecke, Heike, et al.. (2013). The Burden and Impact of Vertigo: Findings from the REVERT Patient Registry. Frontiers in Neurology. 4. 136–136. 85 indexed citations
5.
Cowie, Martín, S. Cure, F. Bianic, et al.. (2011). Cost-Effectiveness of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters in the Treatment of Chronic Heart Failure: Results of Markov Modelling in a UK Setting. European Journal of Heart Failure. 13(6). 681–689. 24 indexed citations
6.
Goodall, G, Maria Paola Costi, Jesús Reviriego, et al.. (2011). Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España. Endocrinología y Nutrición. 58(7). 331–340. 11 indexed citations
7.
Goodall, G, Maria Paola Costi, Jesús Reviriego, et al.. (2011). Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition). 58(7). 331–340. 11 indexed citations
8.
Pollock, Richard F., William J. Valentine, G Goodall, & Michael Brändle. (2010). Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. Swiss Medical Weekly. 140(4344). w13103–w13103. 17 indexed citations
9.
Mittendorf, Thomas, et al.. (2009). Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost‐effectiveness analysis in the German setting. Diabetes Obesity and Metabolism. 11(11). 1068–1079. 29 indexed citations
10.
Goodall, G, et al.. (2009). The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocrine Disorders. 9(1). 19–19. 49 indexed citations
11.
Scherbaum, Werner A., G Goodall, Katrina Erny-Albrecht, et al.. (2009). Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Effectiveness and Resource Allocation. 7(1). 9–9. 13 indexed citations
12.
Smith‐Palmer, Jayne, B. Curtis, Kristina S. Boye, G Goodall, & Stanley R. Pillemer. (2009). Anti‐CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis. Diabetic Medicine. 27(2). 189–196. 3 indexed citations
13.
Brändle, Michael, et al.. (2009). Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International Journal of Clinical Pharmacology and Therapeutics. 47(8). 501–515. 24 indexed citations
14.
Kalsekar, Anupama, et al.. (2009). The Impact of Obesity on Adverse Cardiovascular Outcomes in the General Population and in patients with Type 2 Diabetes. SHILAP Revista de lepidopterología. 2. CMED.S3479–CMED.S3479. 2 indexed citations
15.
16.
Goodall, G, Johan Jendle, William J. Valentine, et al.. (2008). Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. International Journal of Clinical Practice. 62(6). 869–876. 11 indexed citations
17.
Palmer, James L., et al.. (2008). Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Current Medical Research and Opinion. 24(5). 1417–1428. 18 indexed citations
18.
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giovanni Viscogliosi Breakdown of academic impact, for papers by J.‐P. Le Floch Breakdown of academic impact, for papers by D.V. Coppini Breakdown of academic impact, for papers by Takeshi Momotsu Breakdown of academic impact, for papers by Jeff Mahon Breakdown of academic impact, for papers by Ida Juul Rasmussen Breakdown of academic impact, for papers by Luc Sauriol Breakdown of academic impact, for papers by Gerardo Corigliano Breakdown of academic impact, for papers by Shuangling Xiu
Rankless by CCL
2026